DENVER, Colo., May 09, 2024 (247marketnews.com)- Can-Fite BioPharma Ltd. (NYSE:CANF) stated that the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for Namodenoson, for the Company's ongoing Phase IIb clinical study.

“The IND activation for the treatment of MASH patients with Namodenoson, opens the gate for the enrolment of US based patients and will contribute to the heterogeneity of the population of this study,” commented Can-Fite's CEO, Motti Farbstein. ” As we are already enrolling patients for this study, we hope that in the next few months, we will complete recruitment. We are committed to improve the lives of MASH patients and based on the efficacy of the drug in the Phase IIa study, we are proud to develop a new potential treatment to address this disease.”

The post FDA Grants Can-Fite IND Clearance for a Phase IIb Study appeared first on 24/7 MarketNews.

COMTEX_452115495/2900/2024-05-09T08:33:27